Quarterly report pursuant to Section 13 or 15(d)

Noncontrolling Interest

v3.19.1
Noncontrolling Interest
3 Months Ended
Mar. 31, 2019
Noncontrolling Interest [Abstract]  
NONCONTROLLING INTEREST

NOTE 16 – NONCONTROLLING INTEREST

 

As of March 31, 2019, Dr. Yu Zhou, director and Co-Chief Executive Officer of GenExsome, who owned 40% of the equity interests of GenExosome, which is not under the Company’s control. The following is a summary of noncontrolling interest activities in the three months ended March 31, 2019.

 

    Amount  
Noncontrolling interest at December 31, 2018   $ (862,200 )
Net loss attributable to noncontrolling interest     (99,113 )
Foreign currency translation adjustment attributable to noncontrolling interest     (1,198 )
Noncontrolling interest at March 31, 2019   $ (962,511 )